Literature DB >> 1613536

The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.

G Nikkhah1, J C Tonn, O Hoffmann, H P Kraemer, J L Darling, W Schachenmayr, R Schönmayr.   

Abstract

In this study we assessed the influence of patient- and drug-specific parameters in the short-term MTT-chemosensitivity assay in 150 primary cell cultures derived from human brain tumors. In 45 patients the MTT assay was directly compared with the CFA (Colony Forming Assay). Resistance was 10-20% higher in the MTT assay than in the CFA, but there was a good agreement in both assays, that more malignant gliomas had a higher in vitro chemosensitivity against ACNU and BCNU. Overall the results demonstrate, that there is no uniform correlation between the in vitro chemosensitivity and the histopathological classification of the tumors, which corresponds well to the clinical situation. On the basis of this study we suggest prospective clinical trials with the MTT assay in human brain tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613536     DOI: 10.1007/bf00172942

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

1.  Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization Grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Düsseldorf University.

Authors:  N Roosen; J C Kiwit; E Lins; M Schirmer; W J Bock
Journal:  Cancer       Date:  1989-11-15       Impact factor: 6.860

2.  Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy.

Authors:  C A North; R B North; J A Epstein; S Piantadosi; M D Wharam
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

3.  Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.

Authors:  A P Bowles; C G Pantazis; W Wansley
Journal:  J Neurosurg       Date:  1990-08       Impact factor: 5.115

4.  Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.

Authors:  V A Levin; K T Wheeler
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations.

Authors:  C A Bertelsen; V K Sondak; B D Mann; E L Korn; D H Kern
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

Review 6.  Chemotherapy for malignant gliomas.

Authors:  P L Kornblith; M Walker
Journal:  J Neurosurg       Date:  1988-01       Impact factor: 5.115

7.  Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy.

Authors:  T E Moon; S E Salmon; C S White; H S Chen; F L Meyskens; B G Durie; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 8.  The role of chemotherapy in the treatment of gliomas in adults.

Authors:  D J Stewart
Journal:  Cancer Treat Rev       Date:  1989-09       Impact factor: 12.111

9.  Human central nervous system and plasma pharmacology of mitoxantrone.

Authors:  R M Green; D J Stewart; H Hugenholtz; M T Richard; M Thibault; V Montpetit
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

10.  The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.

Authors:  I J Stratford; M A Stephens
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

View more
  21 in total

1.  Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.

Authors:  A Boiardi; A Silvani; A Pozzi; L Fariselli; G Broggi; A Salmaggi
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects.

Authors:  Chandni Valiathan; Jose L McFaline; Leona D Samson
Journal:  DNA Repair (Amst)       Date:  2011-11-30

3.  Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.

Authors:  A Boiardi; A Salmaggi; A Pozzi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

4.  Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.

Authors:  A Boiardi; M Eoli; A Salmaggi; E Lamperti; A Botturi; G Broggi; L Bissola; G Finocchiaro; A Silvani
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

5.  Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors.

Authors:  M Senkal; J C Tonn; R Schönmayr; W Schachenmayr; U Eickhoff; M Kemen; E Kollig
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

6.  Chemotherapy in experimental brain tumor, part 1: in vitro colorimetric MTT assay.

Authors:  C M Hand; J R Vender; P Black
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

7.  Theobroma cacao: Review of the Extraction, Isolation, and Bioassay of Its Potential Anti-cancer Compounds.

Authors:  Zainal Baharum; Abdah Md Akim; Taufiq Yap Yun Hin; Roslida Abdul Hamid; Rosmin Kasran
Journal:  Trop Life Sci Res       Date:  2016-02

8.  Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.

Authors:  Marco Saini; Florian Roser; Samii Hussein; Madjid Samii; Mattia Bellinzona
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

9.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

10.  Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy.

Authors:  Vladimir Balik; Peter Mirossay; Peter Bohus; Igor Sulla; Ladislav Mirossay; Marek Sarissky
Journal:  Cell Mol Neurobiol       Date:  2009-03-14       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.